We assessed dte association between radial bone mass and vitamin D consider& age, estrogen sufticiency and thiazide use in 373 warnen, aged 20-80 years in P ;eeographically detincd arca. We measured cortical bone mass of the radius, using photon abwrptiometry. and se25hydroxyvitti D and 1,25dihydroxyvitamin D, using preliminarychromatogtaphy andprotein-binding assay.
(4-51 and may be causally related to the observed impairment of intestinal calcium absorption with age [6] [7] [8] . One mechanism for diminished calcium absorption might be impaired l-a hydroxylation of 2Shydroxyvitamin D, in the kidney, to its hormonally-active form, substantially impeding the promotion of a calcium-binding protein. Other mechanisms might include alteration in secondary factors related to the 1,25-dihydroxyvitamin D response to serum calcium [9] . This paper characterizes the factors associated with different levels of 1,25-d& hydroxyvitamin D including measures of menopause and estrogen sufficiency, age, aaid use of thiazide medication in a large population of women who reside in a geographically-defined area. The levels of 1,25-dihydroxyvitamin D are related to radial bone mass, considering important factors previously observed to influence bone mass in this population [lO,ll] .
Materials and Methods
Women from a single rural community who were aged 20-80 years were invited to participate in a study of bone mass. Women who were institutionalized in nursing homes or diagnosed with cancer, kidney disease, liver disease or other debilitating conditions which resulted in immobilization or loss of capacity to climb three stairs were excluded from the study recruitment (n = 108). To minimize effects of in-or out-migration, participants eligible for recruitment had to have resided in the community at least 5 years. Pregnant women (n = 15) were excluded from study participation, as were women who reported their heritage as being other than Northern European (n = 10). Four hundred sixty-eight women (n = 468) met these eligibility criteria and, of these, 89% @I= 417) participated in the study, as shown in Fig. 1 . All measurements were collected during the two month period from June 1 to August 1.
Serum vitamin D analysis was completed for 373 women which represents 80% of the eligible 468 women. Of the 417 study participants, four refused the blood drawing, seven had samples of insufficient quantity for analysis of all products specified in the protocol, and blood from 33 women could not be drawn using a single venipuncture probe specified in the protocol. Serum was drawn off from the centrifuged blood, aliquoted and stored in vials frozen at -20 "C for a time period of l-63 days and then stored at -70 "C until analysis. The serum was protected from light oxidation and had a single thaw at time of analysis. Levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were quantified following extraction and preliminary chromatography by competitive protein binding assay using labelled calf thymus or radio-receptor assay as previously described [12] .
Radial bone mass was measured using a Norland 278 Photon Ahsorptiometer (Norland Corporation; Fort Atkinson, WI) whose system is based on the method of Cameron [13, 14] . Bone mass was measured at a site one-third the distance between the styloid process and the olecranon and expressed as the amount of bone mineral, in grams, relative to box width, ..+,_..__ ._. __.. -=-.+md in renrimeters. Our orecision, expressed as the coefficient of variation from two measurem~mts of 30 persons and relocation of the measurement site, was 2.7%.
Other variables
The interviewer observed labels of currently used nutrition supplement preparations for nutrient quantity; the participant was asked to recall the number, frequency and duration of use. A 15item food frequency instrument was limited to selected foods high in calcium and vitamin D. Its time frame was the previous 2 years. Participants were asked to recall the consumption frequency of selected foods and shown color photographs to help quantify serving sizes as large, medium or small. Calcium values were assigned to foods using USDA Handbook #8. Vitamin D values were assigned to food based upon the McCance and Widdowson Food Composition Tables  [U] or nutrient composition information to reflect food fortification. All nutrient values were transformed to common logarithms to normalize their distributions.
An interviewer-administered questionnaire was used to gather information about factors which might affect bone mineralization. That questionnaire was the information source for variables about menopause and sunlight exposure. Current medications were observed by the interviewers for drug name, dose and prescribed frequency of use, with actual use based on participant's :self-report. For purposes of analysis, women were defined as postmenopausal if they reported no longer having menses because of surgery or satttrai history. If menopause was uncertain, a wo- regression analyses to observe the nature and strength of that relationship [17] .
Correlates with 1,25-dihydroxyviromin D
The mean values (+ SD) for 25-hydroxyvitamin D and 1,25diiydroxyvitamin D in women aged 20-80 years are shown in Table 1 , according to S-year intervals. There was no significant correlation (r = 0.06) between values for 2S-hydroxyvitamin D Table 1 Mean (F SD) values in J-year age intervals of radial bone mass (g/cm*), serum 2% hydroxyvitarnin D ("g/ml) and i,25-hydroxyvitamin D (pg/ml) of 373 women and 1,25-dihydroxyvitamin D whether data were or were not stratified by age or menopause status.
The level of serum 1,25-dihydroxyvitamin D was influenced by menopausal status, including estrogen replacement, as well as age, of the woman. As shown in Table 2 Table 2 The comparison of 1,25-dihydroxyvitamin D (pg/ml) levels in premenopausal women vs. postmenopausal women who are described according to current estrogen replacement status 
Number Mean -t SEM Menopausal status Number Mean f SEM P-value
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Because we observed differences in 1.25.dihydroxyvitamin D levels based on menopausal status, the relationships between 1,25-dihydroxyvitamin D and bone mass are reported according to the menopausal status of the women. Furthermore, we evaluated the relationship singly and after considering the influence of other factors we had previously observed to be associated with bone mass measurement as presented in Table 3 Table 3 ). The full model included an important interaction term between thiazide use and 1,25-dihydroxyvitamin D, indicating that the magnitude of the association between bone mass and 1,25-dihydroxyvitamin D differed according to thiazide status (see Table 3 , part A). To more fully explore the relationship, bone mass and 1,25-dihydroxyvitamin D levels were evaluated in estrogen-deficient postmenopausal women according to current thiazide use. Among women not using thiazide, senun 1,2Sdihydroxyvitamin D was associated negatively with bone mass [see Table 3 , parts B and C) after considering other explanatory factors, However, among the 52 thiazide users, the 1,25-dihydroxyvitamin D measurement was not significantly related to bone mass after considering other explanatory factors.
Among premenopausal women, the influence of 1,Sdihydroxyvitamin D accounted for 5% of the explained variability in a model that had included the influence of alcohol consumption. age of first pregnancy and calcium intake. This model explained approximately 19% of the variability of radial bone mass measurements observed in premenopausal women, and was developed in previous work of associating life style factors with maximal bone mass [lo] .
Because decrease in bone mass with age is an aggregation of several processes [18] , studies of 1,25-dihydroxyvitamin D are important for understanding those factors which may influence calcium absorption and calcium metabolism with aging. We have described some relationships between 1,25-dihydroxyvitamin D, bone mass, estrogen status, age, and thiatide use, cross-sectionally, in a large populatio?l of non-institutionalized women from a geographically defined area across a substantial age range.
Several hypotheses have been advanced to describe the contribution of 1,25-dibydroxyvitamin D to bone loss and osteoporosis. At menopause, bone tissue may become more sensitive to mobilization by parathyroid hormone (F'TH) and 1,25-dihydroxyvitamin D [19] . This could icsii!: ir. :ippression of FTH and 1,2Sdihydroxy-vitamin D production, decrease in calcium absorption and increased calcium turnover from bone. Another hypothesis suggests that declining renal function due to aging may impede appropiate I-a-hydroxylation, including pamthyroid phosphate response [1, 20] .
Our data sugL"+ !hat decline in the measurable quantity of 1,25-dihydroxyvitamin D may be, in part, associated with estrogen status, with lower 1,25-dihydroxyvitamin D !eveis more likely to be associated with estrogen deficiency. Increased levels of 1,25-dihydroxyvitamin D3 have been reported in studies of estradiol administration of postmenopausal women [16, 21] and in promenopausal women contrasted to postmenopausal women [22] . Additionally, a finding of lower 1,2.5-dihydroxyvitamin D levels in menopause without estrogen replacement is not inconsistent with the animal literature which suggests that estrogen deficiency may decrease 1.a-hydroxylase activity directly [23, 24] or indirectly via the parathyroid gland [25] . In contrast, a prospective study of 1.25-dihydroxyvitamin D and vitamin D binding protein showed no association with the hormone and carrier with postmenopausal bone loss; however, the small sample size would have limited the investigators to a significant observation only when change in 1,25-dihydroxyvitamin D was greater than 25% [26] . Though the basis for an estrogen effect remains unclear, the apparent consistency of this observation in animal studies, clinical populations and a geographically defined general population suggebis that association is not artifactual.
There are inconsistencies among studies describing levels of circulating 1,25-dihydroxyvitamin D in older persons, an issue of importance since decline in calcium absorption with aging may contribute to bone loss with age. Some studies indicate reduction in mean 1,25-diiydroxyvitamin D levels [l-3!, other reports suggest minimal age-related reduction [21, . Some of the inconsistencies in findings may be attributable to differences in criteria for study selection, age of the study subjects, numbers of patients evaluated, and assay variability. Initial examination of our data suggested that 1,25-dihydroxyvitamin D levels were lower in older members of this female population. However, closer examination of the findings suggested menopausal change was a potent explanatory factor of 1,25-dihydroxyvitamin D levels. Thus, when postmenopausal women are compared with premeco~x!-sal women, there was an observed effect on 1,25-dihydroxyvitamin D levels. However, when one examined the levels among postmenopausal women without estrogen replacement, age-associated decline is less prominent. We, like Tsai et al. [2] , observed a modest decline in 1,25_dihydroxyvitamin D levels among postmenopausal women (without current estrogen replacement) which is more pronounced after approximately age 70. This is consistent with the reports of decreases in calcium absorption with aging, especially after age 70 [1, 6, 7] . We demonstrated a negative and significant association between bone mass and 1,25-dihydroxyvitamin D values in a geographically defined population. Even following adjustment for age, hormonal vitamin D levels rose, cross-sectionally, as bone mass values declined. Greater 1,25dihydroxyvitamin D levels associated with a lower bone mass is not indicative of a primary reduction in 25-hydroxyvitamin D-l-a-hydroxylase. This is consistent with the findings of Riggs et al. [9] and Sorensen et al. [3] , whose experimental administration of parathyroid hormone to osteoporotic and age-comparable normal postmenopausal women did not support the hypothesis that patients with osteoporosis have a primary reduction in 25-hydroxyvitamin D-1-a-hydroxylase reserve capacity. Prince et al. [25] observed, similar renal reserve synthetic capacity in comparing postmenopausal women to premenopausal women. However, the negative relationship with bone does suggest that either calcium absorption response in the gut is not efficient, that calcium excretion is excessive, that a new PTH-vitamin D set point has been generated which is associated with estrogen deficiency [31] , or that there is potent stimulation of bone resorption independent of calcium absorption.
Though bone mass decline was associated with a rise in 1,25-dihydroxyvitamin D levels, this finding is not observed among postmenopausal women using thiazide anti-hypertensive medication. In that group, there is no relationship between bone mass and 1,2S-dihydroxyvitamin D values. Furthermore, these thiazide-using post-menopausal women, as a group, had lower 1,2Sdihydroxyvitamin D values. Previous investigators have reported that thiazide use increases renal conservation of calcium and use of thiazide medication has been associated with greater bone mass in both women.
[ll] and men [32] .
We cannot address the issue whether the cause of bone loss and fracture in osteoporosis is associated with decreased bone formation or increased bone resorption. Our study is cross-sectional in nature and measures radial bone mass. In spite of these limitations, evidence from this examination of 1,25-dihydroxyvitamin D levels and bone mass is consistent with increased bone rrsorption rather than decreased osteoblast formation in bone loss of aging, particularly in women more likely to be estrogen deficient. The evidence includes the observation that greatervitamin D le\~ls were associated with lower bone mass except in women using a calcium-conserving medication, thiazide. Furthermore, calcium intake was also negatively associated with l,ZS-dihydroxyvitamin D levels.
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